|
|
Article: Positive preliminary results reported on AVR118.
- Article from:
- Biotech Business Week
- Article date:
- December 8, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 DEC 8 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) reported that preliminary results from the first 15 cachectic (wasting) AIDS patients treated with the company's novel immunomodulator AVR118 showed improvement in appetite, weight gain or stability, and enhanced quality of life in all the patients.
None of the 15 patients reported any significant side effects from AVR118 (formerly known as Product R) therapy. Cachexia is a state of body malnutrition and wasting with loss of body fat and lean body weight.
The 15 patients who completed the trial included eight males, five on highly active antiretroviral therapy (HAART), and ...